Follows people with coronary artery disease treated with a long heart stent
Observes the Ultimaster Nagomi stent in adults with narrowed heart arteries.
Plain-language title generated from the registry record
Registry title: LONG NAGOMI™ PMCF STUDY
Key facts
- Where
- Cabueñes, Ciudad Real, Elche, Huelva, León, Málaga, Pamplona, Santander, and Seville, SpainSee the 10 sites
Where in Spain
- Hospital Universitario de CabueñesCabueñes, SpainTaking people
- Hospital General Universitario de Ciudad RealCiudad Real, SpainTaking people
- Hospital General Universitario de ElcheElche, SpainTaking people
- Hospital Universitario Juan Ramon JimenezHuelva, SpainTaking people
- Hospital Universitario De LeonLeón, SpainTaking people
- Hospital Universitario Regional de MálagaMálaga, SpainTaking people
- Hospital Universitario Virgen de la VictoriaMálaga, SpainTaking people
- Hospital Universitario de NavarraPamplona, SpainTaking people
- Hospital Universitario Marqués de ValdecillaSantander, SpainTaking people
- Hospital Universitario Virgen del RocioSeville, SpainTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Fundación EPIC
- Trial code
- NCT07399002
- Record updated
- 11 September 2026
- Original description
The study is designed as a prospective, multi-center, observational PMCF (post-market clinical follow-up) study of the Ultimaster Nagomi™ _stent (lengths of 38, 44 and 50 mm) in the treatment of coronary artery disease according to the indications approved in the CE marking.Read full original descriptionShow less
Long Coronary Lesions: Safety and Performance of the Ultimaster Nagomi™ Stent in This Setting With a One-to-one Approach -One Lesion, One Stent- LONG NAGOMI™ PMCF STUDY
The study is designed as a prospective, multi-center, observational PMCF (post-market clinical follow-up) study of the Ultimaster Nagomi™ _stent (lengths of 38, 44 and 50 mm) in the treatment of coronary artery disease according to the indications approved in the CE marking.
Inclusion: Patients who meet ALL inclusion criteria will be included:; Patients aged ≥ 18 years AND; Patients who according to standard practice of the hospital are amenable to PCI as indicated and considered adequate according to the European clinical practice guidelines on coronary revascularization AND; Patients with at least one lesion fulfilling the "long lesion criteria" suitable for a single stent approach AND; Patients who have been informed of the characteristics of the study and have provided written informed consent AND; Intention to treat all lesions with the Ultimaster Nagomi™ stent.
Exclusion: Patients with acute coronary syndrome (ACS) under conditions of cardiogenic shock (Killip class 4); Patients with contraindications or hypersensitivity to sirolimus; Patients in whom any surgery requiring general anesthesia is planned, comorbidity or indication likely necessitating the discontinuation of dual anti-platelet therapy before the recommended duration of dual anti-platelet therapy per the ESC or national guidelines; Patients must not meet any of the following exclusion criteria:; Patients who expressly decline to participate in the study; Pregnant or breastfeeding women; Patients with a life expectancy of less than 2 years; Patients included in other clinical trials that did not reach the primary objective.